SAFETY AND OUTCOMES OF CONCOMITANT AFICAMTEN AND DISOPYRAMIDE USE AND WITHDRAWAL IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: AN ANALYSIS OF REDWOOD-HCM COHORT 3, SEQUOIA-HCM, AND FOREST-HCM TRIALS
Disopyramide (diso) is used in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is a selective cardiac myosin inhibitor that reduces hypercontractility without affecting calcium transients. We investigated concomitant use and withdrawal in patients with oHCM.
Authors
- Theodore P. Abraham (ORCID: https://orcid.org/0000-0001-8966-6906)
- Roberto Barriales‐Villa (ORCID: https://orcid.org/0000-0002-6721-3487)
- Perry Elliott (ORCID: https://orcid.org/0000-0003-3383-3984)
- Artur Oręziak (ORCID: https://orcid.org/0000-0003-3318-3643)
- Stephen B. Heitner (ORCID: https://orcid.org/0000-0003-2189-1474)
- Daniele Massera (ORCID: https://orcid.org/0000-0002-9499-6456)
- Sara Saberi (ORCID: https://orcid.org/0000-0003-4473-6725)
- Amy Wohltman
- Ozlem Bilen (ORCID: https://orcid.org/0000-0002-3078-5262)
- Jenny Wei (ORCID: https://orcid.org/0009-0000-5828-5705)
- Jozef Bartúnek (ORCID: https://orcid.org/0000-0002-4927-1632)
- ANJALI TIKU OWENS (ORCID: https://orcid.org/0000-0002-9669-8495)
- Caroline Coats (ORCID: https://orcid.org/0000-0002-3208-470X)
- Albree Tower‐Rader
- Mark V. Sherrid (ORCID: https://orcid.org/0000-0003-4972-7780)
- Scott David Solomon (ORCID: https://orcid.org/0000-0003-3698-9597)
- Chiara Melloni
- Iacopo Olivotto
- Ahmad Masri (ORCID: https://orcid.org/0000-0002-6390-6526)
- Fady I. Malik (ORCID: https://orcid.org/0000-0002-5597-5759)
- Stuart Kupfer (ORCID: https://orcid.org/0000-0002-5469-1287)
- Michael E. Nassif (ORCID: https://orcid.org/0000-0002-1232-7604)
- Martin S. Maron
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1016/s0735-1097(25)01644-4
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00